Showing 141 - 160 results of 1,026 for search '"Mashhad"', query time: 0.05s Refine Results
  1. 141
  2. 142
  3. 143
  4. 144
  5. 145
  6. 146
  7. 147
  8. 148

    Comparison of the Effects of Vitagnus, Soy, and Vitagnus-soy Capsules on Premenstrual Syndrome in University Students: A Randomized Clinical Trial by Roya Partovi Golshan, Maryam Moradi, Hasan Rakhshandeh, Vahid Ghavami, Seyed Mostafa Moshirian Farahi

    Published 2025-01-01
    “…This study aimed to compare the effects of the Vitagnus, soy, and Vitagnus-soy combination on PMS in students.Methods: This triple-blind, three-arm clinical trial was conducted on 108 students with PMS living in the dormitory of Mashhad University of Medical Sciences from September 2022 to October 2023. …”
    Get full text
    Article
  9. 149
  10. 150
  11. 151
  12. 152
  13. 153
  14. 154
  15. 155

    A Game Theory-Based Approach to Hierarchically Rank Responses to Geological and Geotechnical Risks by Mohammad Amin Ghasvareh, Gholam Reza Lashkaripour, Hossein Sadeghi, Javad Tayyebi

    Published 2024-10-01
    “…To verify the proposed model, as an experimental study, the existing geological and geotechnical risks on line 3 of the Mashhad urban Subway were investigated. Based on the degree of importance, the responses to the desired risks are determined and prioritized in the following. …”
    Get full text
    Article
  16. 156
  17. 157
  18. 158
  19. 159

    Predicting high sensitivity C-reactive protein levels and their associations in a large population using decision tree and linear regression by Somayeh Ghiasi Hafezi, Toktam Sahranavard, Alireza Kooshki, Marzieh Hosseini, Amin Mansoori, Elham Amir Fakhrian, Helia Rezaeifard, Mark Ghamsary, Habibollah Esmaily, Majid Ghayour-Mobarhan

    Published 2024-12-01
    “…This study was conducted on a population of 9704 males and females aged 35 to 65 years recruited from the Mashhad Stroke and Heart Atherosclerotic Disorder (MASHAD) cohort study. …”
    Get full text
    Article
  20. 160

    Short-term effects of empagliflozin on preventing contrast induced acute kidney injury in patients undergoing percutaneous coronary intervention, a randomised trial by Zeinab Sadat Hosseini, Mohammad Javad Jamili, Behzad Ensan, Ghazaleh Donyadideh, Bahram Shahri, Hamid Eshraghi, Susan Darroudi, Mohsen Moohebati

    Published 2025-01-01
    “…This research conducted a double-blind randomized clinical trial involving 121 patients undergoing PCI referred to Ghaem Hospital, Mashhad, Iran from 2022 to 2023. Participants were randomly assigned to receive empagliflozin (10 mg daily) or a placebo, starting one day before PCI and continuing for two days post-procedure. …”
    Get full text
    Article